Mechanisms of molecular resistance and predictors of response to biological therapy in inflammatory bowel disease

The Lancet Gastroenterology and Hepatology

Fecha de publicación: 1 november 2018

DOI: https://doi.org/10.1016/S2468-1253(18)30265-6

Autores: Prof Raja Atreya, MD., Prof Markus F Neurath, MD.

Background: Biological therapy has led to marked improvements in treatment of patients with inflammatory bowel disease, and an increasing number of drugs has been approved for treatment. However, only a subgroup of patients responds to therapy, highlighting the need to identify biomarkers for therapeutic response to allow personalised medicine in inflammatory bowel disease.

Seguir leyendo